Stammers Alfred H, Tesdahl Eric A, Mongero Linda B, Stasko Andrew J, Weinstein Samuel
SpecialtyCare, Nashville, Tennessee.
J Extra Corpor Technol. 2017 Dec;49(4):231-240.
During cardiac surgery, myocardial protection is performed using diverse cardioplegic (CP) solutions with and without the presence of blood. New CP formulations extend ischemic intervals but use high-volume, crystalloid-based solutions. The present study evaluated four commonly used CP solutions and their effect on hemodilution during cardiopulmonary bypass (CPB). Records from 16,670 adult patients undergoing cardiac surgery with CPB between February 2016 and January 2017 were reviewed. Patients were classified into one of four groups according to CP type: 4-1 blood to crystalloid (4:1), microplegia (MP), del Nido (DN) and histidine-tryptophan-ketoglutarate (HTK). Covariate-adjusted estimates of group differences were calculated using multivariable logistic and linear mixed effects regression models. The primary end point was intraoperative transfusion of allogeneic red blood cells (RBCs), with a secondary end point of intraoperative hematocrit change. Among all patients, 8,350 (50.1%) received 4:1, 4,606 (27.6%) MP, 3,344 (20.1%) DN, and 370 (2.2%) HTK. Both 4:1 and MP were more likely to be used in patients undergoing coronary revascularization surgery, whereas DN and HTK were seen more often in patients undergoing valve surgery ( < .001). The highest volume of crystalloid CP solution was seen in the HTK group, 2,000 [1,754, 2200], whereas MP had the lowest, 50 [32, 67], < .001. Ultrafiltration usage was as follows: HTK-84.9%. DN-83.7%, MP-40.1%, and 4:1-34.0%, < .001. There were no statistically significant differences on the primary outcome risk of intraoperative RBC transfusion. However, statistically significant differences among all but one of the pair-wise comparisons of CP methods on hematocrit change ( < .05 or smaller), with MP having the lowest predicted drift (-7.8%) and HTK having the highest (-9.4%). During cardiac surgery, the administration of different CP formulations results in varying intraoperative hematocrit changes related to the volume of crystalloid solution administered.
在心脏手术期间,心肌保护通过使用含血和不含血的多种心脏停搏液(CP)来实现。新的CP配方延长了缺血时间,但使用的是大容量的晶体基溶液。本研究评估了四种常用的CP溶液及其在体外循环(CPB)期间对血液稀释的影响。回顾了2016年2月至2017年1月期间16670例接受CPB心脏手术的成年患者的记录。根据CP类型,患者被分为四组之一:4比1血液与晶体液(4:1)、微停搏液(MP)、德尔尼多液(DN)和组氨酸 - 色氨酸 - 酮戊二酸液(HTK)。使用多变量逻辑和线性混合效应回归模型计算组间差异的协变量调整估计值。主要终点是术中异体红细胞(RBC)输血,次要终点是术中血细胞比容变化。在所有患者中,8350例(50.1%)接受4:1溶液,4606例(27.6%)接受MP,3344例(20.1%)接受DN,370例(2.2%)接受HTK。4:1和MP在接受冠状动脉血运重建手术患者中更常使用,而DN和HTK在接受瓣膜手术患者中更常见(<0.001)。HTK组晶体CP溶液用量最高,为2000[1754,2200],而MP组最低,为50[32,67],<0.001。超滤使用情况如下:HTK组为84.9%,DN组为83.7%,MP组为40.1%,4:1组为34.0%,<0.001。术中RBC输血的主要结局风险无统计学显著差异。然而,除一对比较外,CP方法在血细胞比容变化方面的所有成对比较均有统计学显著差异(<0.05或更小),MP的预测漂移最低(-7.8%),HTK最高(-9.4%)。在心脏手术期间,不同CP配方的使用导致与所给予晶体溶液量相关的术中血细胞比容变化各异。